ApoB

ApoB (apolipoprotein B) is a protein found on every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a). Because each of these particles carries exactly one ApoB, the ApoB measurement directly counts the number of atherogenic particles, making it a more accurate cardiovascular risk marker than LDL cholesterol alone.

Conventional cholesterol panels measure the total cholesterol content of LDL particles, but this is indirect — it measures what's inside the particles, not the number of particles themselves. The problem: two people can have identical LDL cholesterol but very different particle counts. Small, dense LDL particles carry less cholesterol per particle, so someone with many small particles may have the same LDL-C as someone with fewer large particles — while having substantially higher cardiovascular risk.

ApoB solves this by directly counting atherogenic particles. Each LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB molecule. Measuring ApoB therefore counts the total number of particles capable of entering the arterial wall and contributing to plaque. Multiple large studies (including Mendelian randomization analyses) have shown that ApoB is a more accurate predictor of cardiovascular events than LDL-C, particularly in individuals with metabolic syndrome or high triglycerides.

Target ranges depend on risk category. Optimal ApoB for primary prevention is below 80 mg/dL; for those with elevated cardiovascular risk or existing atherosclerosis, below 60 mg/dL is recommended. Standard labs often list "normal" up to 120 mg/dL, which is not aligned with current longevity-oriented cardiology.

The primary dietary levers for ApoB reduction are: reducing saturated fat and refined carbohydrates (both raise ApoB through different mechanisms), increasing fiber (particularly soluble fiber from oats, beans, and psyllium), and increasing polyunsaturated fats. Exercise has modest ApoB effects but is more impactful on particle quality and triglyceride patterns.

For women, ApoB deserves particular attention from age 40 onward as the protective effects of estrogen decline. The historical emphasis on "HDL protects women" has been overstated — ApoB is the more actionable and accurate target. Checking ApoB every 1–2 years beginning in the 30s establishes a longitudinal baseline; values that drift upward during perimenopause warrant intervention before they reach conventional treatment thresholds.

Guide associé

Termes associés

The Ava Method

Discover your Lifestyle Biological Age in 6 minutes.